SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is hovering near the $80,000 psychological resistance level, with the community actively debating whether this represents a breakout point or a potential trap for short sellers. Market participants are closely watching US Treasury bond strategies and potential policy developments, viewing recent volatility as a tug-of-war between bullish sentiment and lingering skepticism over the sustainability of current price levels.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is trending as investors react to the company establishing a $1.59 billion USD cash pool, with the community actively debating whether the stock's recent performance is hindered by share dilution despite Bitcoin's ongoing rally toward record levels. Traders are closely watching for a potential short squeeze, with many expressing bullish sentiment on the expectation of a significant price gap-up in the coming week.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is capturing significant community attention ahead of its highly anticipated earnings report, with sentiment divided between those expecting another blowout quarter and skeptics concerned about hardware price hikes and the sustainability of AI-related spending. Traders are actively debating the impact of these earnings on the broader semiconductor sector and the potential for a volatile market reaction.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is trending after raising over $900 million at a $6.3 billion valuation for its robotics subsidiary, Dogotix, drawing investment from major firms like IDG Capital, Tencent, and Alibaba. While community sentiment is divided, many investors are debating whether this massive influx of capital for its 'Physical AI' and humanoid robot ambitions creates a long-term valuation disconnect with its core EV business.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is gaining investor attention due to aggressive Bitcoin accumulation and potential for a short squeeze, with community members actively discussing the company's BTC treasury growth and its comparison to other major digital asset proxies. Investors are closely monitoring its price action in relation to Bitcoin's recovery as they look for signs of a sustained breakout.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as investors await confirmation of the 80th clinical event from the REGAL Phase 3 trial, with community discussion focused on potential buyout interest and the impact of recent cancer vaccine data. While retail sentiment remains highly active, participants are divided between excitement over clinical progress and skepticism regarding unverified reports and the trial's timeline.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BitMine Immersion Technologies is trending as investors rally behind its substantial Ethereum treasury and aggressive share buyback strategy, fueling community excitement around a potential breakout. The conversation is heavily focused on the stock's sensitivity to crypto market conditions and optimism that the firm will outpace direct crypto investments as institutional adoption grows.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors digest news that the FDA has extended the target review date for its Duchenne muscular dystrophy treatment to November 22 following the submission of a major amendment. The community is actively debating the significance of the shift toward an upper-limb function indication and speculating on the probability of approval as investors brace for potential institutional activity.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba stock is in focus as investors weigh a $10.2 billion capital raise aimed at bolstering AI infrastructure against concerns regarding share dilution and increased capital expenditures. While some market participants express skepticism over the dilution and recent profitability declines, the community remains heavily engaged with bullish sentiment, closely watching the company's progress in the competitive AI video generation market.

BTCT is a TRC20 token that is 100% backed by Bitcoin (BTC). The reserve addresses are published for anyone to audit.  Bitcoin uses peer-to-peer technology to operate with no central authority or banks; managing transactions and the issuing of bitcoins is carried out collectively by the network. Bitcoin is open-source; its design is public, nobody owns or controls Bitcoin and everyone can take part. Through many of its unique properties, Bitcoin allows exciting uses that could not be covered by any previous payment system.

Bitcoin TRC20

BTCT is seeing significant momentum and heightened community discussion driven by its strategic expansion into AI computing infrastructure and the broader rally in Bitcoin prices. Traders are closely watching the stock for potential breakout levels, though some express caution regarding the impact of recent share registration filings on the ticker's price action.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$TRVI The end is nearing and it will be a BO right around $30 or so. Looking good here.

"Tune Guy"

BrotherBarrett

StockTwits Web

Trevi Therapeutics Inc

 The end is nearing and it will be a BO right around $30 or so. Looking good here.

Brett Ermilio

@Bfunk17 That would be amazing but that’s quite the price tag. We’ll see

StockTwits for iOS

 That would be amazing but that’s quite the price tag. We’ll see

Biotech

@hmandude No competition now in both Refractory and IPF and they will be first to market for both. Non-IPF emerging as well. They have the field (at the moment) and their trial results have been very strong. Certainly, the 2B BOs for single indication companies haven&#39;t gone well but we have many shots at the board here. A 5B price tag is within reason IMO.

 No competition now in both Refractory and IPF and they will be first to market for both. Non-IPF emerging as well. They have the field (at the moment) and their trial results have been very strong. Certainly, the 2B BOs for single indication companies haven't gone well but we have many shots at the board here. A 5B price tag is within reason IMO.

@Bfunk17  Yeah I can see that blue sky scenario. When the market cap was in the $1-2B range, I was thinking buyout would be $3B. Now with the GSK fail, maybe higher. It still seems like a pretty big risk for big pharma to pay $5B and have to run the trials though. I sold half my position on Friday.

Rainer Zufall

BO would need to be a premium price. $300 million cash in the bank and now limited potential completion across IPF/ILD and RCC and trials all positive. CEO has continually pointed to Verona as path and pricing potential but would be later in 2027 or early 2028. If sold now, no reason to sell if they believe in the drug unless material premium. Obviously riskier path as camlipixant failure highlights

Scott Shulze

  Yeah I can see that blue sky scenario. When the market cap was in the $1-2B range, I was thinking buyout would be $3B. Now with the GSK fail, maybe higher. It still seems like a pretty big risk for big pharma to pay $5B and have to run the trials though. I sold half my position on Friday.

@hmandude I always liked 3B or so as well. But now with the strength of TRVIs trials and GSK going down, it really does lock in an extra 1B or so. It will be interesting.

 I always liked 3B or so as well. But now with the strength of TRVIs trials and GSK going down, it really does lock in an extra 1B or so. It will be interesting.